Related Experiment Video
Updated: Jun 4, 2026
12:09
Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4
Published on: December 31, 2013
TRPV1: a therapy target that attracts the pharmaceutical interests
Rong Xia1, Kim Dekermendjian, Elke Lullau
1DECS, Cell, Protein, and Structure Sciences, AstraZeneca R&D, Mölndal SE-43183, Sweden. Rong.Xia@astrazeneca.com
Advances in Experimental Medicine and Biology
|February 4, 2011
Summary
Transient Receptor Potential Vanilloid 1 (TRPV1) channels integrate pain signals. TRPV1 antagonists show promise for treating chronic pain by selectively inhibiting pain signaling at its source.
Area of Science:
- Neuroscience
- Pharmacology
- Pain Research
Background:
- Transient Receptor Potential Vanilloid 1 (TRPV1) is a key ion channel in sensory neurons.
- TRPV1 integrates noxious stimuli like heat, vanilloids, and protons, playing a critical role in pain signaling.
- Dysfunctional TRPV1 signaling is implicated in chronic pain conditions.
Purpose of the Study:
- To review the physiological and pathological roles of TRPV1.
- To summarize the pharmacology of TRPV1 agonists and antagonists.
- To provide an update on TRPV1-targeted therapies in clinical trials.
Main Methods:
- Literature review of TRPV1 physiology and pathology.
- Pharmacological profiling of TRPV1 modulators.
- Analysis of clinical trial data for TRPV1 therapies.
Main Results:
- TRPV1 acts as a crucial signal integrator in nociceptors.
- TRPV1 antagonists are hypothesized to alleviate chronic pain by targeting the initiation site of pain signaling.
- Several TRPV1 therapies have advanced into clinical development.
Conclusions:
- TRPV1 antagonists offer a promising therapeutic strategy for chronic pain management.
- Understanding TRPV1 pharmacology is essential for developing effective pain treatments.
- Ongoing clinical trials will determine the efficacy and safety of TRPV1-based therapies.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...